While there is a paucity of research on RNA methylation status as a therapeutic target, histone-modifying agents such as histone deacetylase inhibitors and histone methyltransferase inhibitors are already in phase 1/2 clinical testing for AML, glioma, cholangiocarcinoma, and myelodysplastic syndromes (126–129). This evidence concerns the gene PRDM9 and myelodysplastic syndrome.